Swisse owner H&H says supplement sector ‘highly resilient’ as sales up nearly 5%
Swisse’s parent company Health and Happiness Group (H&H Group) saw its supplements sales rise by nearly five per cent in FY24, despite overall revenues dipping.
Total revenue was pulled down by underperforming categories like paediatric nutrition and infant milk formula.
Total revenue shrunk 6.3 per cent from RMB14bn (US$1.9bn) to RMB13.1bn (US$1.8bn), but a breakdown showed supplements sales up by 4.9 per cent.
BYHEALTH FY24 sales down for all key brands amid stiff market competition
China dietary supplement firm BYHEALTH recorded significant sales drops in FY24, with one of the reasons being increased competition from both international and domestic brands.
Sales across all its key brands, including its eponymous brand BYHEALTH and bone and joint health brand Keylid dropped 30 per cent or so.
The company also outlined its 2025 plans, including the launch of its first OTC product and infant nutrition business plans in South East Asia.
Haleon reaps strong results from localised strategies in China
Haleon’s localisation strategy for its China supplement products has been key to its overall APAC business success, with the firm also announcing a focus on healthy ageing in the country.
In FY24, bone and joint health brand Caltrate and multivitamin brand Centrum have reported “double-digit” and “high-single” digit sales growth in APAC, and these were largely driven by sales from China.
Localisation of products and services was a key factor driving its growth in China.
Danone reaps strong infant formula sales in China, India in FY24
Danone says it has continued to gain shares in China’s infant formula market, while sales in India, especially the super premium sector, was “two times faster” than the market in FY24.
“Infant milk formulas have posted yet another year of solid growth”, said Juergen Esser, Group Deputy CEO when presenting the company’s FY24 financial results.
Strong growth in Danone’s Aptamil infant formula brand was seen throughout the whole of last year, he added.
Nestle says HMO innovation brings China’s infant formula sales back on track
Nestle says “science-based innovation with human milk oligosaccharides” has brought its underperforming infant formula business in China back on track in FY24.
Nestle was referring to innovations such as Sinergity - a proprietary blend of probiotics and six human milk oligosaccharides (HMOs).
The blend is used in its new range of infant formulas launched under its brand Nestle NAN in Hong Kong for instance.
Blackmores major profit contributor to Kirin health science business in FY24
Blackmores was the major profit contributor to Kirin’s health science business in FY24, followed by FANCL, while its ingredient arm Kyowa Hakko Bio suffered further losses.
Normalised operating profit of the subsidiary acquired in 2023 was JPY6bn (US$39.39m) last year, while revenue was up 116.1 per cent from JPY32bn (US$210.09m) to JPY69.1bn (US$453.66m).
FANCL, on the other hand, brought in a revenue of JPY34.5bn (US$226.5m), and a normalised operating profit of JPY2bn (US$13.1m).
